MSLN and mesothelioma: Recently, a phase I/II trial of anetumab ravtansine, an anti-MSLN ADC, plus pembrolizumab, compared to pembrolizumab alone in mesothelioma found that higher sMSLN levels were associated with worse progression free survival (PFS) for patients treated with anetumab ravtansine.There was no difference in PFS based on sMSLN levels for the pembrolizumab control arm10.